Intellia Therapeutics (NASDAQ:NTLA) Given New $88.00 Price Target at Chardan Capital
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at Chardan Capital from $94.00 to $88.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s target price would suggest a potential upside of 455.21% from the stock’s […]
24 Oct 21:56 · The Markets Daily